A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/14/2002	WO2002090325A2 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	WO2002090314A1 Pyruvate derivatives
11/14/2002	WO2002089919A2 Usage of zinc for preventing tnf-induced pathology during cancer therapy
11/14/2002	WO2002089916A1 Method of preventing type 2 diabetes with aerosolized insulin
11/14/2002	WO2002089858A1 Azo compounds for type i phototherapy
11/14/2002	WO2002089856A1 Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
11/14/2002	WO2002089854A1 Gene transfer of angiogenic factor for skin disease
11/14/2002	WO2002089852A1 Soluble protein-polymer systems for drug delivery
11/14/2002	WO2002089845A1 Remedies for sepsis
11/14/2002	WO2002089843A1 Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
11/14/2002	WO2002089842A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	WO2002089835A2 Pharmaceutical dosage form of amorphous nelfinavir mesylate
11/14/2002	WO2002089834A1 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
11/14/2002	WO2002089833A2 Methods and compositions for prevention of angioproliferation
11/14/2002	WO2002089832A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	WO2002089831A1 Preventives/remedies for nephritis
11/14/2002	WO2002089829A2 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer
11/14/2002	WO2002089828A2 Interferons in the treatment of ischemia
11/14/2002	WO2002089819A1 Glycoconjugates and uses thereof
11/14/2002	WO2002089817A2 Anti-virus agent
11/14/2002	WO2002089805A2 Use of regularly scheduled high dose intravenous methotrexate therapy
11/14/2002	WO2002089796A2 Methods for selective immunomodulation using pimecrolimus
11/14/2002	WO2002089789A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	WO2002089780A2 Antiviral compounds
11/14/2002	WO2002089779A2 Combined preparation for the prophylaxis and/or therapy of nerve cell and/or glia cell damage using a novel method of treatment
11/14/2002	WO2002089775A1 Coated granules based on angiotensin-converting enzyme inhibitor
11/14/2002	WO2002089773A2 Pharmaceutical compositions comprising cyclosporin
11/14/2002	WO2002089747A2 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	WO2002089744A2 Combined treatments and methods of treatment of mycoplasma and mycoplasma-like organism infections
11/14/2002	WO2002089739A2 Peptide deformylase activated prodrugs
11/14/2002	WO2002089733A2 Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
11/14/2002	WO2002089732A2 Therapeutic compisitions and methods for the inhibition of angiogenesis
11/14/2002	WO2002089731A2 Agents for treatment of hcv and methods of use
11/14/2002	WO2002089730A2 Compounds and methods for the modulation of cd154
11/14/2002	WO2002089658A2 Microvascular free flaps for local or systemic delivery
11/14/2002	WO2002079393A9 Dynamic action reference tools
11/14/2002	WO2002077010A9 Method of preventing t-cell mediated responses by map proteins
11/14/2002	WO2002074326A3 Urocortin-iii and uses thereof
11/14/2002	WO2002070679A3 Peptide fragments, derived from human telomerase reverse transcriptase
11/14/2002	WO2002068465A9 Novel p53-inducible protein
11/14/2002	WO2002068457A3 Antiangiogenic peptides derived from endostatin
11/14/2002	WO2002066051A8 Use of the g-csf as adjuvant treatment in connective tissue recontruction
11/14/2002	WO2002064779A3 Peptide inhibitors of cellular proliferation
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002062373A3 Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
11/14/2002	WO2002062370A3 Stabilization of hypoallergenic, hyperdigestible previously reduced proteins
11/14/2002	WO2002055152A8 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
11/14/2002	WO2002053167A3 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
11/14/2002	WO2002050116A3 Adhesion molecule protein
11/14/2002	WO2002046215A3 Basb221 polypeptides and polynucleotides encoding basb221 polypeptides
11/14/2002	WO2002040635A3 HUMAN RNase H1 MUTANTS
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002015661A8 Inhibitors of hiv replication and method of treatment of hiv infections
11/14/2002	WO2001031036A9 Modified viral surface proteins which bind to cells of tumor vasculature
11/14/2002	WO2001024831A9 Polymer stabilized neuropeptides
11/14/2002	WO2001019842A9 Subunit optimized fusion proteins
11/14/2002	US20020170079 Polypeptide for use in the treatment, prevention ad diagnosis of tumors
11/14/2002	US20020170077 Nucleotide sequences coding polypeptide for use in te diagnosis, prevention and treatment of atherosclerosis, ischemia/ reperfusion injuries, hypertension, restenosis and arterial inflammation
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169328 Mitomycin C and pyrrolo(1,2-a)benzimidazole; exposing microorganisms to first agent which induces expression of protein which inactivates mitomycin c then to second agent which is activated by same protein which inactivates first
11/14/2002	US20020169318 Novel thrombin inhibitors
11/14/2002	US20020169304 Nucleotide sequences coding polypeptide for use in the classification, diagnosis, prevention and treatment of downe's syndrome and alzheimers's diseases
11/14/2002	US20020169303 Novel PTP-20, PCP-2, BDP1, CLK, and SIRP proteins and related products and methods
11/14/2002	US20020169302 Compositions isolated from bovine mammary gland and methods for their use
11/14/2002	US20020169301 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cell proliferative disorders
11/14/2002	US20020169300 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of colon cancer
11/14/2002	US20020169295 Nucleotide sequences coding protein for use in the treatment, diagnosis and prevention of tumors and inflammatory bowel disease
11/14/2002	US20020169292 Human glycoprotein hormone for use in the prevention and treatment of metabolic and sexual disorders
11/14/2002	US20020169291 Interleukin-18 mutants, their production and use
11/14/2002	US20020169290 Nuclceotide sequences for use in the diagnosis, and prevent of multile sclerosis, viral infections, cancer, tumors, or tumour angiogenesis, and Chrohn's disease
11/14/2002	US20020169289 Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
11/14/2002	US20020169288 Therapeutic composition for treating or preventing staphylococcal infection
11/14/2002	US20020169287 Nucleotide sequences coding polypeptide for use in the treatment of eating, dieteticad energy disorders
11/14/2002	US20020169285 Polypeptide for use in the diagnosis, prevention and treatment of protozoan infections
11/14/2002	US20020169284 Nucleotide sequences coding polypeptide for use in the treatment of tumors, nervous system, virus, and visoin disorders
11/14/2002	US20020169283 Nucleotide sequences coding polypeptides for use in the treatment of autoimmune diseases
11/14/2002	US20020169280 Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
11/14/2002	US20020169279 Peptide for use in the prevention and treatment of bacterial infections
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169162 Device and method for treating conditions of a joint
11/14/2002	US20020169158 Administering to a patient a (tetrahydra-4,7,8,10 methyl-1 (chloro-1-phenyl)-6 (methoxy-4-phenyl-carbamoyl)-9 pyrido (4',3'-4,5)thieno (3,2-f)triazolo-1,24 (4,3-a) diazepine-1,4) as antiangiogenesis agent; anticarcinogenic agent
11/14/2002	US20020169139 Single gene encoding aortic-specific and striated-specific muscle cell isoforms and uses thereof
11/14/2002	US20020169137 Preventing or inhibiting pathological beta-amyloid plaque formation in conditions such as Alzheimer's disease
11/14/2002	US20020169136 For detection of Babesia microti infection; in particular, invention is antigenic epitopes of such an antigen and the use of such polypeptides and antigenic epitopes for the serodiagnosis and treatment of B. microti infection
11/14/2002	US20020169133 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
11/14/2002	US20020169132 Polypeptides
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169129 In quantities sufficient to substantially increase hemoglobin production
11/14/2002	US20020169128 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
11/14/2002	US20020169127 Compositions and methods for diagnosing or treating psoriasis
11/14/2002	US20020169126 E1A gene based anti-cancer therapy that targets cancers and tumors involving phospho-Akt expression (and/or Akt activation) and/or phospho-p38 downregulation (and/ or p38 inactivation)
11/14/2002	US20020169124 Treatment of balance impairments
11/14/2002	US20020169123 Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
11/14/2002	US20020169122 Chondrogenic potential of human bone marrow-derived CD105+ cells by BMP
11/14/2002	US20020169121 Inhibiting tumor growth by inhibiting transcriptional activity of the transcription factor ATF2 which gives tumor cells apoptosis resistance; treating melanoma
11/14/2002	US20020169119 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169118 TNF receptors, TNF binding proteins and DNAs coding for them
11/14/2002	US20020169117 (RANK); RANK is a member of the TNF superfamily; used to regulate an immune response
11/14/2002	US20020169114 Formulation of boronic acid compounds

1 ... 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 ... 3163